Results in the present study show that combined treatment of γ-tocotrienol with PPARγ antagonist decreased the protein and mRNA levels of COX-2 and PGDS, as well as decreased PGD2 synthesis in +SA mammary tumor cells. This evidence concerns the gene PTGS2 and breast cancer.